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ABSTRACT
Objective: To determine the relationship between
renal function and visit-to-visit blood pressure (BP)
variability in a cohort of primary care patients.
Design: Retrospective cohort study from routinely
collected healthcare data.
Setting: Primary care in Nijmegen, the Netherlands,
from 2007 to 2012.
Participants: 19 175 patients who had a measure of
renal function, and 7 separate visits with BP readings
in the primary care record.
Outcome measures: Visit-to-visit variability in
systolic BP, calculated from the first 7 office
measurements, including SD, successive variation,
absolute real variation and metrics of variability shown
to be independent of mean. Multiple linear regression
was used to analyse the influence of estimated
glomerular filtration rate (eGFR) on BP variability
measures with adjustment for age, sex, diabetes, mean
BP, proteinuria, cardiovascular disease, time interval
between measures and antihypertensive use.
Results: In the patient cohort, 57% were women,
mean (SD) age was 65.5 (12.3) years, mean (SD)
eGFR was 75.6 (18.0) mL/min/1.73m2 and SD systolic
BP 148.3 (21.4) mm Hg. All BP variability measures
were negatively correlated with eGFR and positively
correlated with age. However, multiple linear
regressions demonstrated consistent, small magnitude
negative relationships between eGFR and all measures
of BP variability adjusting for confounding variables.
Conclusions: Worsening renal function is associated
with small increases in measures of visit-to-visit BP
variability after adjustment for confounding factors.
This is seen across the spectrum of renal function in
the population, and provides a mechanism whereby
chronic kidney disease may raise the risk of
cardiovascular events.
INTRODUCTION
Hypertension is a major vascular risk factor,
and average blood pressure (BP) correlates
with cardiovascular disease and death.1
Recently, visit-to-visit variability in BP mea-
surements has been shown to convey an add-
itional independent risk for cardiovascular
events and to be associated with all-cause
mortality in the general population.2 3 BP
variability is reproducible within individuals
over time in clinical trials4 and in observa-
tional data from routine care.4 The cardio-
vascular prognostic signiﬁcance of BP
variability is increasingly recognised, and the
variability is not explained by poor medica-
tion adherence.5
Increased BP variability has been observed
in small groups of patients with relatively
advanced renal disease under specialist hos-
pital care. In a small hospital cohort,
visit-to-visit BP variability was independently
associated with albuminuria and with
increased renal vascular resistance as assessed
by Doppler ultrasound.6 A study of 56 patients
with non-diabetic chronic kidney disease
(CKD) indicated a correlation between
Strengths and limitations of this study
▪ We studied blood pressure (BP) variability in a
patient cohort generalisable to primary care
where the majority of patients with chronic kidney
disease are diagnosed and monitored, as previ-
ously BP variability in chronic kidney disease
(CKD) has only been studied in patients with
advanced renal disease under specialist care.
▪ We examined measures of BP variability that are
independent of mean BP, which have been
shown to have greater prognostic significance
than mean BP alone.
▪ We were not able to assess the effect of different
exposures to antihypertensive medication.
▪ We did not have access to data on cardiovascular
outcomes to test the clinical significance of
visit-to-visit variability in this patient cohort.
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indices of BP variability and the rate of decline in renal
function.7 In type 2 diabetes, visit-to-visit variability in sys-
tolic BP correlates with the level of albuminuria, ankle
brachial pressure index,8 and the probability of develop-
ing new albuminuria.9 In a set of secondary care patients
with substantial renal impairment, there was a correlation
between BP variability and a composite outcome of death
and cardiovascular events.10 In patients on haemodialysis,
visit-to-visit variability in BP is an independent predictor
of vascular events, but this is complicated by the depend-
ence of BP in this context on intradialytic ﬂuid gain.11
However, as BP variability increases with mean BP, and
renal disease is associated with increased mean BP, the
relationship between BP variability and renal impair-
ment can only be established using metrics of BP vari-
ability that have been shown to be independent of mean
BP.12 None of the renal studies mentioned above
reported statistics of BP variability that were demon-
strated to be independent of the mean BP and, there-
fore, an evidence gap remains concerning whether
declining renal function is associated with BP variability.
It is important to establish whether there is a real rela-
tionship between renal impairment and increased BP
variability because the link might be causal and have
important implications for therapy in CKD. Analysis of
large sets of routinely collected healthcare data has
demonstrated that CKD is an important independent
risk factor for cardiovascular disease even after control-
ling for other known risk factors.13 14 The prevalence of
CKD is around 5–10%, and the majority of patients with
CKD are managed by non-specialists or primary care
physicians.15 16 Given that a substantial proportion of
the population have early stage CKD, it is therefore
crucial to establish whether early stage CKD is associated
with increased BP variability, as there could be major
implications for population cardiovascular risk factor
monitoring and treatment.
We therefore sought to determine whether renal func-
tion was associated with visit-to-visit BP variability using a
large dataset of routinely collected healthcare data.
METHODS
We retrospectively deﬁned a patient cohort (age
≥18 years) using routinely collected healthcare data
from 47 primary care practices in the Nijmegen region,
the Netherlands, with a combined registered population
of 207 468 people, as part of the CONTACT study
(Consultation of Nephrology by Telenephrology Allows
optimal Chronic kidney disease Treatment in primary
care), Netherlands Trial Registration code 2368, with
approval from the Medical Research Ethics Committee
Arnhem/Nijmegen, registration number 2010/187.
Data included demographic details, medical history
with conditions diagnosed in the course of routine clin-
ical practice, BP measurements, antihypertensive pre-
scribing and renal function between 1 January 2008 and
1 January 2011. We did not seek to include patients
receiving dialysis in this study population. The Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
formula was used to calculate estimated glomerular ﬁltra-
tion rates (eGFRs) using the ﬁrst creatinine measure-
ments in the time period, which were either standardised
to isotope dilution-mass spectrometry (IDMS), or subject
to the appropriate correction factor for laboratories using
the Jaffé technique.17 CKD-EPI eGFRs have been shown
to correlate better with measured GFRs than eGFRs
obtained with the Modiﬁcation of Diet in Renal Disease
(MDRD) study formula.18 The ﬁrst seven ofﬁce BP mea-
surements were used to calculate variability metrics, as this
approach has been shown to optimise reproducibility.12
Dutch primary care physicians and practice nurses have
free access to the Dutch College of General Practitioners
guideline on cardiovascular risk management for a clear
description of standardised ofﬁce BP measurement,
which is in agreement with international standards.
Given that blood pressure variability is associated with
mean BP, we calculated BP variability independent of
mean (VIM) BP using standard formulae for measures
that have prognostic signiﬁcance for cardiovascular
events.12 For the systolic and diastolic BP of individuals
with at least seven BP measures, we calculated the SD, suc-
cessive variation (SV), average real variability (ARV), and
transformed these to be independent of mean BP12 (see
online supplementary information for formulae).
Observed associations between renal function and BP
variability (systolic BP metrics described above and also
including maximum systolic BP), may be confounded by
other predictors of variability, and we therefore tested the
association between renal function and measures of BP
variability using multiple stepwise linear regression adjust-
ing for age, sex, mean BP, diabetes, history of cardiovascu-
lar disease (including vascular events, arrhythmia and
heart failure), proteinuria, time interval between BP mea-
sures and class of antihypertensive drug prescribed. We
included mean BP as a covariate to ensure that the effect
of mean BP was truly adjusted for in regressions testing
the relationship between VIM statistics and eGFR.
Analyses were carried out using R (V.3.0.1) and SPSS V.21.
RESULTS
Among the 207 468 total registered population, 162 562
were over the age of 18 years, of whom 63 073 (39%)
had renal function measured during the study period.
Of these, 19 175 (30%) had at least seven BP measure-
ments recorded at different visits. Table 1 lists the fea-
tures of the group which had a mean age of 65.5 years, a
mean blood creatinine concentration of 85.3 µmol/L
(0.97 mg/dL), a mean eGFR of 75.6 mL/min/1.73 m2
and a mean systolic BP of 148.3 mm Hg.
The mean time interval from the ﬁrst to the ﬁnal
seventh BP measurement was 22 months (SD
11 months). Mean systolic BP rose with age (R=0.19,
p<0.001) and with falling eGFR (R=−0.11, p<0.001).
Correlation analysis of transformed BP variability
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measures was consistent with their independence from
mean BP (R values; SD independent of mean (SDIM)
−0.009, p=0.23; SV independent of mean (SVIM) −0.009,
p=0.22; ARV independent of mean (ARVIM) −0.01,
p=0.15). Online supplementary table S1 shows the results
of curve ﬁtting to generate the transformed variables.
Table 2 shows the correlations between mean systolic
BP and its variability with deteriorating eGFR and with
increasing age. All measures of intraindividual BP vari-
ability increase progressively with declining eGFR and
with increasing age.
The relationships of eGFR and age with SDIM, as an
exemplar of the associations with VIM, are shown in
ﬁgure 1A, B.
Multiple stepwise regression analysis was performed to
examine the association between renal function and BP
variability. Table 3 shows the standardised β coefﬁcients
and associated p values from multiple regression ana-
lyses of eGFR on BP variability metrics using, age, sex,
mean systolic BP, diabetes, cardiovascular disease, pro-
teinuria, interval between BP measures and the class of
antihypertensive drug prescribed as covariates (medica-
tion classes are not shown, see online supplementary
table S2). Non-standardised coefﬁcients for categorical
variables are shown in online supplementary table S3).
Lower eGFR was consistently associated with increasing
measures of BP variability (both with and without trans-
formation to be independent of mean BP), as evidenced
by the signiﬁcant negative standardised β coefﬁcients
across the regressions in the presence of potential con-
founders. Although the presence of proteinuria was not
associated with any measure of BP variability, a history of
cardiovascular disease was positively associated with
increased BP variability. All classes of antihypertensive
medication were positively associated with measures of
BP variability where signiﬁcant relationships were
observed (see online supplementary table S2).
Greater BP variability was associated with longer time
intervals between BP measures, as evidenced by the posi-
tive coefﬁcients where signiﬁcant relationships were
observed.
DISCUSSION
Both mean BP and visit-to-visit BP variability increased
with age and with worsening renal function in this large
community-based population. Further analysis with mul-
tiple linear regression demonstrated that worsening
renal function remains signiﬁcantly associated with
increased BPVIM, even after adjustment for age, sex, dia-
betes, history of cardiovascular disease, mean systolic
blood pressure, interval between BP measures, protein-
uria and the class of antihypertensive drug prescribed.
This is important because visit-to-visit BP variability over
the medium term is a strong predictor of cardiovascular
outcome independently of mean BP.3 In addition, this
relationship between renal function and BP variability
may explain, in part, the association between renal func-
tion and cardiovascular disease, which remains even
after controlling for other established cardiovascular risk
factors.15
Hitherto, the relationship between renal disease and
BP variability has not been studied in large unselected
community-based populations. In specialist services
which typically care for patients with advanced renal
disease, or those requiring renal replacement therapy,
visit-to-visit variability in BP has been linked to poorer
renal6 and cardiovascular outcomes.19 In settings, such
as the UK or the Netherlands, where guidelines exist for
specialist referral,20 21 there is substantial enrichment in
specialist service populations for advanced CKD stage,
rapidly declining renal function, or signiﬁcant protein-
uria. Observational studies of these groups for prognos-
tic factors has an uncertain generalisability to the much
Table 1 Demographics of population studied (n=19 175)
Age 65.5 (12.3) years
% Female 57%
CKD-EPI eGFR 75.6 (18.0) mL/min/
1.73 m2
Creatinine 85.3 (23.0) µmol/L or
0.97 (0.26) mg/dL
Diagnosed with diabetes 37.5%
Number of antihypertensive drugs
prescribed (%, proportion of
patients)
0–16.5
1–26.7
2–30.1
3–18.8
4–6.8
5–1.0
6–0.1
Interval between 1st and 7th BP
measure
627 (295) days
Systolic BP at baseline 148.3 (21.4) mm Hg
Continuous data are presented as mean (SD).
BP, blood pressure; CKD-EPI, Chronic Kidney Disease
Epidemiology Collaboration formula; eGFR, estimated glomerular
filtration rate.
Table 2 Correlation of systolic BP metrics with eGFR and
with age
Systolic BP metric
Correlation
with eGFR
Correlation
with age
Mean −0.110*** 0.190***
Maximum −0.121*** 0.178***
SD −0.116*** 0.115***
SV −0.115*** 0.131***
ARV −0.113*** 0.129***
SDIM −0.086*** 0.054***
SVIM BP −0.088*** 0.076***
ARVIM BP −0.086*** 0.075***
***p<0.001.
ARV, average real variability; ARVIM, ARV independent of mean;
BP, blood pressure; eGFR, estimated glomerular filtration rate;
SDIM, SD independent of mean; SV, successive variation; SVIM,
SV independent of mean.
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larger, but less severely affected, population monitored
predominantly by non-specialists or primary care physi-
cians. Furthermore, none of the previous studies of
renal disease have used metrics of BP variability that
have been shown to be independent of mean BP, and
so, do not clearly distinguish between the effects of
raised systolic BP and BP variability.
The results of the regression analyses showed a con-
sistent positive relationship between the presence of
cardiovascular disease and BP variability, a ﬁnding that
is consistent with the known prognostic signiﬁcance of
BP variability.22 Importantly, the time interval between
BP measures was positively associated with BP variabil-
ity, indicating that longer durations between measures
were associated with greater variability. This counters
the hypothesis that associations between greater BP
variability and reduced renal function are an artefact
of acute illness where clinical monitoring will be more
frequent, or due to increased monitoring at the time
of initiation of antihypertensive drugs. If acute illness
or the initiation of antihypertensive therapy was
responsible for increasing BP variability, one would
expect greater variability to be associated with shorter
time intervals between BP measures in a period of
clinical instability or medication change. We presented
standardised coefﬁcients for all included variables in
order to facilitate a clear clinical interpretation of the
relative contributions of the predictors of the BP vari-
ability measures.
A limited post hoc analysis of around 2000 patients
selected for the ASCOT-BPLA trial showed a weak rela-
tionship between blood creatinine and BP variability, but
the trial design undermines the generalisability of this
analysis to representative patient populations.22 The
Figure 1 Renal function and age, both associated with blood pressure variability. Colours indicate the number of data points in
each shaded area of the plot. The number of patients represented by each coloured polygon, that is, the data frequency, is
indicated by the colour scale. Contours are added to aid visualisation of the shape of the frequency distribution across the
two-dimensional plot. The contours are derived from kernel density estimation of the data frequency, and represent the
boundaries of intervals of equal magnitude in the data frequency. The regression line is shown. (A) The relationship between SD
independent of mean (SDIM) and estimated glomerular filtration rate (eGFR). (B) The relationship between SDIM and age.
Table 3 Standardised β coefficients and associated p values from multiple linear regressions of eGFR on measures of BP
variability adjusted for potential confounders (medication classes not shown)
Measure of BP
Variability
eGFR
Std β
Age
Std β
Sex
Std β
Mean BP
Std β
Vascular disease
Std β
BP interval
Std β
Diabetes
Std β
SD −0.04*** − 0.06*** 0.37*** 0.07*** − −0.06***
ARV −0.04*** 0.02*** 0.06*** 0.31*** 0.06*** 0.02* −0.035***
SRV −0.04*** 0.02* 0.07*** 0.32*** 0.06*** 0.02* −0.03***
Max systolic −0.02*** −0.01* 0.03*** 0.88*** 0.03*** − −0.03***
SDIM −0.05*** − 0.07*** −0.04*** 0.08*** − −0.07***
ARVIM −0.04*** 0.03* 0.06*** −0.04*** 0.07*** 0.02* −0.04***
SRVIM −0.05*** 0.03** 0.07*** −0.04*** 0.07*** 0.02* −0.041***
*p<0.05, **p<0.01, ***p<0.001.
ARV, average real variability; ARVIM, ARV independent of mean; BP, blood pressure; eGFR, estimated glomerular filtration rate; SDIM, SD
independent of mean; SRV, successive real variability; SRVIM, SRV independent of mean.
Coefficients shown if included in stepwise multiple regression.
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study excluded anyone with a creatinine of >200 µmol/L
(2.26 mg/dL), with clinically important renal disease,
with secondary hypertension (which could include renal
disease), or any concomitant disease requiring calcium
channel blockers, angiotensin converting enzyme in-
hibitors, β blockers, or diuretics. These criteria would
likely exclude the majority of patients with chronic
kidney disease. Further, the study excluded anyone
<55 years of age, eGFRs were not reported, and it is
unclear whether creatinine assays were standardised to
IDMS values. Creatinine is inﬂuenced by both age and
renal function—in part because of age-related changes
in muscle mass—and the analysis was weakened in this
older trial population by the comparison of creatinine
values across different ages.
The relationship we observed between CKD and BP
variability in a wider population demonstrates that, even
in the early stages of renal dysfunction, BP variability is
present at a level associated with signiﬁcant cardiovascu-
lar risk. The measures of variability (ARV, SV and those
transformed to be independent of mean) in eGFR
ranges corresponding to CKD stage 4 in this study are
similar to those seen in cohorts of patients with transient
ischaemic attack (TIA) in the UK-TIA trial and the
European Carotid Surgery Trial.12 Furthermore, the
timeframe of BP variability measurement in this study
(mean time between BP measures of 104 days) is consist-
ent with the time frames between repeat BP measures
during follow-up in the trials establishing increased BP
variability and its prognostic signiﬁcance.12 22
Our study has some limitations. The population
studied exists in a healthcare context where the value of
treating hypertension is recognised, and this is likely to
reduce the slope of the relationship between mean sys-
tolic BP and eGFR. In addition, the variability associated
with the estimation of renal function,16 and intrinsic
error will result in regression dilution bias. However, this
will bias the study towards the null hypothesis, such that
the strength of the relationship between renal function
and BP variability will be underestimated rather than
overestimated. Error associated with the measurement of
BP variability will widen the conﬁdence limits associated
with the relationship. Furthermore, while our adjust-
ment for antihypertensive use included drug-class spe-
ciﬁc effects, we were not able to assess the effect of
exposure by examining drop-in and drop-out of treat-
ment, but given that variability may be affected by some
drugs more than others,23 this constraint is also likely to
reduce rather than enhance the associations that we
have found. The ﬁndings are limited to patients with
multiple BP readings taken at their general practice, and
at least one measure of renal function. Nevertheless,
despite these limitations, we have found consistent and
signiﬁcant associations between measures of renal func-
tion and BP variability.
Our results demonstrate that the relationship between
eGFR and BP variability exists across the spectrum of
eGFR which corresponds to different stages of CKD.
This relationship is consistent with a causative relation-
ship between diminished eGFR and BP variability, but
causation cannot be established in an observational
study. Nevertheless, this may prove to have clinical use-
fulness in determining vascular risk and prognosis, as we
have demonstrated that BP variability is readily detect-
able and quantiﬁable in retrospective data in the non-
specialist setting.
Studies of the prognostic signiﬁcance of BP variability
in general CKD populations are required as monitoring
BP variability may reﬁne the prediction of cardiovascular
risk. The correlations that we have identiﬁed are of
small magnitude, but they are independent, and given
the population prevalence of CKD, this correlation will
have consequences for cardiovascular risk at the popula-
tion level. Clinical trials are needed in CKD to establish
the value or otherwise for renal and cardiovascular out-
comes of tailoring antihypertensive therapy to minimise
BP variability.
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